TD Cowen Maintains Buy on Medline, Lowers Price Target to $45

Benzinga Newsdesk www.benzinga.com Negative 64.9%

Neg 64.9% Neu 0% Pos 0%

TD Cowen analyst Charles Rhyee maintains Medline (NASDAQ:MDLN) with a Buy and lowers the price target from $53 to $45.

Comments

No comments yet. Be the first!